Grundlæggende statistik
| CIK | 837490 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Mera Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| October 15, 2021 |
EX-99.9 CUST CONTRCT 2 e3191contract.htm GENERAL SERVICE AGREEMENT THIS GENERAL SERVICE AGREEMENT (the “Agreement”) dated this 9th day of October 2021 BETWEEN: All Your Foods USA INC of 8275 S Eastern Ave, Las Vegas, NV 89123, USA (the “Client”) - AND - Three Tomatoes Catering of 2520 W 29th Avenue Denver, CO 80211 (the “Contractor”). BACKGROUND: A. The Client is of the opinion that the Contractor |
|
| October 15, 2021 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement 8-K 1 e31918-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) : October 9, 2021 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 333-23460 04-3683628 (State or other jurisdicti |
|
| September 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) : September 13, 2021 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 333-23460 04-3683628 (State or other jurisdiction of incorporation) (Com |
|
| September 10, 2021 |
Mera Pharmaceuticals, Inc. Profit & Loss November 1, 2020 through September 8, 2021 EXHIBIT 99b Mera Pharmaceuticals, Inc. Profit & Loss November 1, 2020 through September 8, 2021 Nov 1, ?20 - Sep 8, 21 Ordinary Income/Expense Expense Corporate Registration/Licensin 4,734.08 Transfer Agent and Filing Fees 4,155.00 Total Expense 8,889.08 Net Ordinary Income -8,889.08 Net Income -8,889.08 |
|
| September 10, 2021 |
Mera Pharmaceuticals, Inc. Balance Sheet As of September 8, 2021 EXHIBIT 99a Mera Pharmaceuticals, Inc. Balance Sheet As of September 8, 2021 Sep 8, 21 ASSETS 0.00 LIABILITIES & EQUITY Liabilities Current Liabilities Accounts Payable Accounts Payable 38,649.08 Total Accounts Payable 38,649.08 Total Current Liabilities 38,649.08 Total Liabilities 38,649.08 Equity Preferred Stock - Series A 1.00 Preferred Stock - Series B 1.00 Common Stock 54,777.00 Additional Pa |
|
| September 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) : September 10, 2021 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 333-23460 04-3683628 (State or other jurisdiction of incorporation) (Com |
|
| June 30, 2021 |
All Your Foods USA Inc. Balance Sheet As of October 31, 2020 EX-99.1 2 e2880ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 All Your Foods USA Inc. Balance Sheet As of October 31, 2020 TOTAL ASSETS Current Assets Bank Accounts Business Advantage Chk - 9515 (9515) 12,214.12 Total Bank Accounts $ 12,214.12 Accounts Receivable Accounts Receivable (A/R) 315.65 Total Accounts Receivable $ 315.65 Other Current Assets Inventory 376.55 Inventory Asset -3,856.38 Uncategorized |
|
| June 30, 2021 |
8-K 1 e28808-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) : June 28, 2021 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 333-23460 04-3683628 (State or other jurisdiction |
|
| June 17, 2021 |
Manufacturing and Supply Agreement Exhibit 99.1 Manufacturing and Supply Agreement On June 11, 2021 (the “Effective Date”) a Co-Packing Agreement (the “Agreement”) is entered by and between Revive Organics Inc. (“Revive”), a Canadian Corporation, located at 2650 Bristol Circle, Unit 500, Oakville, ON, L6H6Z7 and All Your Foods USA (“AYF”), a US Corporation, located at 8275 S. Easter Avenue, Suite 200, Las Vegas, Nevada, 89123. Wher |
|
| June 17, 2021 |
Entry into a Material Definitive Agreement 8-K 1 e28518-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) : June 10, 2021 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 333-23460 04-3683628 (State or other jurisdiction of i |
|
| June 7, 2021 |
All Your Foods USA Announces Rights Offering for Its Current Shareholders EX-99.1 2 mrpiex991.htm PRESS RELEASE Exhibit 99.1 All Your Foods USA Announces Rights Offering for Its Current Shareholders All Your Foods USA, a group of companies dedicated to delivering quality healthy food to people’s doorsteps, has just introduced a non-dilutive rights offering for all its existing shareholders. June 7, 2021 Las Vegas, NV /Vancouver, BC All Your Foods USA is pleased to annou |
|
| June 7, 2021 |
Material Modification to Rights of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 333-23460 04-3683628 (State or other jurisdiction of incorporation) (Commission |
|
| March 23, 2021 |
Entry into a Material Definitive Agreement 8-K 1 mrpi8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) : March 22, 2021 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 333-23460 04-3683628 (State or other jurisdi |
|
| March 18, 2021 |
8-K 1 mrpi8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) : March 17, 2021 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 333-23460 04-3683628 (State or other jurisdi |
|
| December 21, 2020 |
8-K 1 mrpi8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) : December 12, 2012 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 333-23460 04-3683628 (State or other juri |
|
| July 23, 2013 |
mrpi10k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: October 31, 2011 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Mera Pharmaceuticals, Inc. (Exact name of regi |
|
| July 26, 2012 |
Quarterly Report - QUARTERLY REPORT 10-Q 1 mrpi10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) þ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period endedApril 30, 2011 Or o Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 333-23460 MERA PHARMACEUTICALS |
|
| July 26, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) þ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended January 31, 2011 Or o Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 333-23460 MERA PHARMACEUTICALS, INC. (Exact name of Registrant |
|
| July 26, 2012 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) þ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended July 31, 2011 Or o Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 333-23460 MERA PHARMACEUTICALS, INC. (Exact name of Registrant as |
|
| July 10, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) : June 15, 2012 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 333-23460 04-3683628 (State or other jurisdiction of incorporation) (Commissi |
|
| July 10, 2012 |
EXHIBIT 3.2 CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF MERA PHARMACEUTICALS, INC. (under Section 141 of the Delaware General Corporation Law) The undersigned, being the President of MERA PHARMACEUTICALS, INC., hereby certifies: FIRST: The name of the corporation is MERA PHARMACEUTICALS, INC. SECOND: The amendment of the Certificate of Incorporation effected by this Certificate |
|
| July 10, 2012 |
EX-3.1 2 mrpiex31.htm SERIES C EXHIBIT 3.1 CERTIFICATE OF DESIGNATION, PREFERENCES, AND RIGHTS OF SERIES C CONVERTIBLE PREFERRED STOCK TO THE CERTIFICATE OF INCORPORATION OF MERA PHARMACEUTICALS, INC. PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned Chief Executive Officer of MERA PHARMACEUTICALS, INC., (the “Corporation”), a company organized and existing under the |
|
| July 10, 2012 |
EXHIBIT 10.1 Share Exchange Agreement by and among MERA PHARMACEUTICALS, INC. a Delaware corporation VILLARI FAMILY CENTERS, INC. a Florida corporation and THE SHAREHOLDERS OF VILLARI FAMILY CENTERS, INC. June 14, 2012 Share Exchange Agreement 1 TABLE OF CONTENTS Article I. THE SHARE EXCHANGE 4 Article II. REPRESENTATIONS AND WARRANTIES OF MERA 5 Article III. REPRESENTATIONS AND WARRANTIES OF VFC |
|
| February 10, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: October 31, 2010 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Mera Pharmaceuticals, Inc. (Exact name of registrant as sp |
|
| June 24, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 8-K/A ??????? CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2011 ??????? MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ??????? Delaware 333-23460 04-3683628 (State or other jurisdi |
|
| June 24, 2011 |
EXHIBIT 16.1 June 24, 2011 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Re: Mera Pharmaceuticals, Inc. File 333-23460 Dear Sir or Madam: We have read Item 4.01 of Form 8-K/A of Mera Pharmaceuticals, Inc., and agree with the statements concerning our Firm contained therein. Very truly yours, /s/ Jewett, Schwartz, Wolfe & Associates Hol |
|
| June 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 8-K ??????? CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2011 ??????? MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ??????? Delaware 333-23460 04-3683628 (State or other jurisdict |
|
| June 15, 2011 |
EXHIBIT 16.1 June 14, 2011 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Re: Mera Pharmaceuticals, Inc. File 333-23460 Dear Sir or Madam: We have read Item 4.01 of Form 8-K of Mera Pharmaceuticals, Inc., and agree with the statements concerning our Firm contained therein. Very truly yours, Jewett, Schwartz, Wolfe & Assoc CPA’s /s/ Jewe |
|
| January 31, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 033-23460 NOTIFICATION OF LATE FILING CUSIP NUMBER 58732R103 (Check one): þ Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: October 31, 2010 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Tran |
|
| September 14, 2010 |
10-Q 1 mrpi10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) [X] Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended July 31, 2010 Or [ ] Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 333-23460 MERA PHARMACEUTI |
|
| June 14, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended April 30, 2010 Or o Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 333-23460 MERA PHARMACEUTICALS, INC. (Exact name of Registrant as |
|
| March 16, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) þ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended January 31, 2010 OR o Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 333-23460 MERA PHARMACEUTICALS, INC. (Exact name of Registrant |
|
| January 27, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K þ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2009 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) DELAWARE 033-23460 04-3683628 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer |
|
| November 6, 2009 |
Completion of Acquisition or Disposition of Assets 8-K 1 mrpi8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2009 ——————— MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) ——————— Delaware 333-23460 0 |
|
| September 9, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 mera10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-Q ——————— (Mark one) þ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended July 31, 2009 Or ¨ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 333-23460 ———— |
|
| June 11, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ——————— FORM 10-QSB ——————— (Mark one) þ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended April 30, 2009 Or ¨ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 333-23460 ——————— MERA PHARMACEUTICALS, INC. (E |
|
| March 12, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-Q ??????? ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: January 31, 2009 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 333-23460 |
|
| January 23, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM 10-KSB ? ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2008 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) DELAWARE 033-23460 04-3683628 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 16, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB ? ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2008 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) DELAWARE 033-23460 04-3683628 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employe |
|
| September 9, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-QSB ??????? (Mark one) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2008 Or ? TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 333-23460 ??????? MERA PHARMACEUTICALS, INC. (Ex |
|
| July 25, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2008 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware] 333-23460 04-3683628 (State or other jurisdiction (Commission (I.R.S. Employe |
|
| June 6, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-QSB ??????? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: April 30, 2008 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to ??????? MERA PHARMACEUTICALS, INC. (Ex |
|
| March 10, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ??????? FORM 10-QSB ??????? x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: January 31, 2008 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to ??????? MERA PHARMACEUTICALS, IN |
|
| March 3, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB/A (Mark one) [X] Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Or [ ] Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended April 30, 2007 Commission File Number: 333-107716 MERA PHARMACEUTICALS, INC. (Exact name of Regi |
|
| March 3, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB/A x ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2007 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) DELAWARE 033-23460 04-3683628 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Emplo |
|
| March 3, 2008 |
Mera Pharmaceuticals Inc. 73-4460 Queen Ka'Aharnanu Highway Suite 110 Kailua-Kona, HI 96740 Mera Pharmaceuticals Inc. 73-4460 Queen Ka'Aharnanu Highway Suite 110 Kailua-Kona, HI 96740 March 3, 2008 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street Washington, D.C. 20549 Re: Mera Pharmaceuticals Inc. Form 10-KSB for the Fiscal Year Ended October 3, 2007 Filed February 14, 2008 File Number: 033-23460 Ladies and Gentlemen: Mera Pharmaceuticals Inc. (t |
|
| February 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-KSB x ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2007 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) DELAWARE 333-107716 04-3683628 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employ |
|
| January 30, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): X Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-SAR Form N-CSR For Period Ended: October 31, 2007 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on Form 11-K Transition Report on Form 10-Q Transition Report on Form N-SAR For the Tr |
|
| September 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark one) [X] Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended July 31, 2007 Or [ ] Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 MERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delawa |
|
| June 12, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark one) [X] Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Or [ ] Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended April 30, 2007 Commission File Number: 333-107716 MERA PHARMACEUTICALS, INC. (Exact name of Regist |
|
| March 21, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark one) [X] Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended January 31, 2007 Or [ ] Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 333-107716 MERA PHARMACEUTICALS, INC. (Exact name of Regi |
|
| March 16, 2007 |
NT 10-Q 1 filing408.htm MERA PHARMACEUTICALS INC FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING 033-23460 58732R 10 3 SEC FILE NUMBER CUSIP NUMBER þ Form 10-QSB For Period Ended: January 31, 2007 If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: P |
|
| February 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 - FORM 10-KSB (X) ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2006 Commission file number 333-107716 MERA PHARMACEUTICALS, INC. (NAME OF SMALL BUSINESS ISSUER IN ITS CHARTER) DELAWARE 04-3683628 (State or other jurisdiction of incorporation or organizatio |
|
| January 31, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING 033-23460 58732R 10 3 SEC FILE NUMBER CUSIP NUMBER þ Form 10-KSB For Period Ended: October 31, 2006 If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: PART I - REGISTRANT INFORMATION MERA PHARMACEUTICALS INC Full |
|
| January 30, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING 033-23460 58732R 10 3 SEC FILE NUMBER CUSIP NUMBER ? Form 10-KSB For Period Ended: October 31, 2006 If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: PART I - REGISTRANT INFORMATION MERA PHARMACEUTICALS INC Full |
|
| September 14, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark one) [X] Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended July 31, 2006 Or [ ] Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 333-107716 MERA PHARMACEUTICALS, INC. (Exact name of Registr |
|
| September 9, 2003 |
================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D. |
|
| January 29, 2003 |
EXHIBIT 3.2 CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK OF MERA PHARMACEUTICALS, INC. AND THE EXPRESS TERMS THEREOF DESIGNATION OF SERIES A PREFERRED STOCK. Of the Ten Thousand (10,000) shares of Preferred Stock of Mera Pharmaceuticals, Inc. (the "COMPANY") that are authorized, Two Thousand Four Hundred (2,400) shares shall be designated Series A Preferred Stock. RIGHTS, PREFERENCES AND |
|
| September 21, 2001 |
Filed Pursuant to Rule 424 (b) (3) Registration No. 333-41356 PROSPECTUS SUPPLEMENT DATED SEPTEMBER 21, 2001 (To Prospectus dated February 6, 2001) AQUASEARCH, INC. 20,000,000 Shares Common Stock This Prospectus Supplement together, with the Prospectus listed above, is to be used by certain holders of the above-referenced securities or by their transferees, pledgees, donees or their successors in |
|
| September 21, 2001 |
AQUASEARCH, INC. 21,354,650 Shares Common Stock 424B3 1 aqse424b3-092101a.htm Filed Pursuant to Rule 424 (b) (3) Registration No. 333-41980 PROSPECTUS SUPPLEMENT DATED SEPTEMBER 21, 2001 (To Prospectus dated February 9, 2001) AQUASEARCH, INC. 21,354,650 Shares Common Stock This Prospectus Supplement together, with the Prospectus listed above, is to be used by certain holders of the above-referenced securities or by their transferees, pledgees, |
|
| September 19, 2001 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark one) [X] Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended July 31, 2001 or [ ] Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 33-23460-LA AQUASEARCH, INC. (Exact name of Registrant as sp |
|
| September 17, 2001 |
AQUASEARCH, INC. 9/17/01 Form 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (CHECK ONE): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR [X] Form 10-QSB For Period Ended: July 31, 2001 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition |
|
| June 14, 2001 |
AQUASEARCH, INC. 21,354,650 Shares Common Stock Filed Pursuant to Rule 424 (b) (3) Registration No. 333-41980 PROSPECTUS SUPPLEMENT DATED JUNE 14, 2001 (To Prospectus dated February 9, 2001) AQUASEARCH, INC. 21,354,650 Shares Common Stock This Prospectus Supplement together, with the Prospectus listed above, is to be used by certain holders of the above-referenced securities or by their transferees, pledgees, donees or their successors in conne |
|
| June 14, 2001 |
AQUASEARCH, INC. 20,000,000 Shares Common Stock Filed Pursuant to Rule 424 (b) (3) Registration No. 333-41356 PROSPECTUS SUPPLEMENT DATED JUNE 14, 2001 (To Prospectus dated February 6, 2001) AQUASEARCH, INC. 20,000,000 Shares Common Stock This Prospectus Supplement together, with the Prospectus listed above, is to be used by certain holders of the above-referenced securities or by their transferees, pledgees, donees or their successors in conne |
|
| June 13, 2001 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark one) [X] Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended April 30, 2001 or [ ] Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 33-23460-LA AQUASEARCH, INC. (Exact name of Registrant as s |
|
| May 18, 2001 |
AQUASEARCH, INC. 20,000,000 Shares Common Stock Filed Pursuant to Rule 424 (b) (3) Registration No. 333-41356 PROSPECTUS SUPPLEMENT DATED MAY 17, 2001 (To Prospectus dated February 6, 2001) AQUASEARCH, INC. 20,000,000 Shares Common Stock This Prospectus Supplement together, with the Prospectus listed above, is to be used by certain holders of the above-referenced securities or by their transferees, pledgees, donees or their successors in connec |
|
| May 17, 2001 |
AQUASEARCH, INC. 21,354,650 Shares Common Stock Filed Pursuant to Rule 424 (b) (3) Registration No. 333-41980 PROSPECTUS SUPPLEMENT DATED MAY 17, 2001 (To Prospectus dated February 9, 2001) AQUASEARCH, INC. 21,354,650 Shares Common Stock This Prospectus Supplement together, with the Prospectus listed above, is to be used by certain holders of the above-referenced securities or by their transferees, pledgees, donees or their successors in connec |
